CS1P1 PET Studies of Neuroinflammation in Parkinson Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: [11C]-CS1P1.
- Who it may be relevant to
- Registry conditions: Parkinson Disease. Basic parameters: from 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Parkinson disease (PD) is a progressive neurological disorder strongly linked to advancing age that results in decline in mobility and thinking. Based on prior research, the investigators think that small amounts of inflammation in the brain may contribute to the mobility and thinking problems in people with PD. They are trying to measure inflammation in the brain in order to understand how this inflammation could be contributing to the symptoms of PD. This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called \[11C\]-CS1P1 to identify inflammation in the brain.The goal of this project is to quantify neuroinflammation with \[11C\]-CS1P1 PET and compare to motor and cognitive function in participants with various stages of severity of PD compared to controls.
Interventions
- Drug [11C]-CS1P1
Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.
Primary outcome measures
- PET imaging studies of [11C]-CS1P1 in healthy control participants and participants with Parkinson Disease. [Time frame: At the time of PET scan]
Eligibility criteria
Inclusion criteria
- Parkinson Disease (PD) participants must be at least 50 years old and meet clinical diagnostic criteria of idiopathic PD.
- Control participants must be at least 50 years old and not have PD, no first-degree family member with PD, and no evidence of PD or dementia on examination.
Exclusion criteria
- any history of other neurologic illness (e.g. stroke, seizure, multiple sclerosis)
- history of brain surgery or major head trauma
- major medical/systemic illness
- severe psychiatric illness (e.g. bipolar disorder, schizophrenia)
- major drug abuse
- history of long term use of anti-dopaminergic medication
- chronic treatment with immunomodulatory or anti-inflammatory medications
- weight over 300 lbs
- contraindication to or inability to tolerate MRI
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Other
Study locations
United States · 1 center
- Washington University School of Medicine — St Louis
Identifiers
NCT: NCT06084533 · 202306067